Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) presents treatment challenges, particularly in recurrent squamous histology.
• Immune checkpoint inhibitors (ICIs) represent a significant advancement in NSCLC therapy.
• Nivolumab was the first ICI approved for recurrent squamous NSCLC, demonstrating survival benefits over docetaxel.

Purpose of the Study:

• To review the landscape of immune checkpoint inhibitors in NSCLC.
• To highlight agents targeting the PD-1/PD-L1 pathway and CTLA-4.
• To discuss the role of PD-L1 as a predictive biomarker.

Main Methods:

• Review of clinical trial data and regulatory approvals for ICIs in NSCLC.
• Analysis of agents targeting programmed cell death protein 1 (PD-1) and its ligand, programmed cell death ligand 1 (PD-L1).
• Examination of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors in NSCLC, often in combination therapy.

Main Results:

• Nivolumab showed a survival advantage in recurrent squamous NSCLC.
• Multiple PD-1 inhibitors (e.g., pembrolizumab) and PD-L1 inhibitors (e.g., atezolizumab, durvalumab, avelumab) are under investigation.
• CTLA-4 inhibitors (e.g., ipilimumab, tremelimumab) are being explored, primarily in combination regimens.

Conclusions:

• Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 pathways are crucial in NSCLC treatment.
• PD-L1 expression is a key area of research for patient selection.
• Ongoing research aims to optimize ICI efficacy and identify predictive biomarkers.